Endo Health downgraded to Underperform from Sector Perform at RBC Capital RBC Capital downgraded Endo Health given valuation and concerns regarding the future of the Opana ER franchise due to potential future generics. Price target lowered to $24 from $25.
News For ENDP From The Last 14 Days
Check below for free stories on ENDP the last two weeks.
Endo Health subsidiary receives CE Mark of RetroArc system American Medical Systems, an Endo Health Solutions subsidiary, announced CE Mark of its RetroArc Retropubic Sling System for treatment of female stress urinary incontinence. The system maintains familiar features of transvaginal retropubic sling systems while incorporating new enhancements and the ability to make fine-tuned adjustments to better meet the needs of physicians, the company said.